Search

Your search keyword '"Tsuji, Daiki"' showing total 182 results
Start Over Author "Tsuji, Daiki"
182 results on '"Tsuji, Daiki"'

2. A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-

Author

Tsuji, Daiki, Nakagaki, Shigeru, Yonezawa, Itsuki, Suzuki, Kenichi, Yokokawa, Takashi, Kawasaki, Yohei, Yamaguchi, Takumi, Kawaguchi, Takashi, Hatori, Masahiro, Matsumoto, Takuma, Sakata, Yukio, Yamamoto, Keisuke, Nishimura, Tomoyasu, Kogure, Yuki, Hayashi, Toshinobu, Osawa, Misa, Itoh, Kunihiko, and Watanabe, Masaya

Published
2024
Full Text
View/download PDF

3. Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer

Author

Miyagi, Takehiro, Tsuji, Daiki, Kawasakai, Yohei, Ishikawa, Hiroshi, Tanaka, Rei, Nakao, Masahiko, Nakagaki, Shigeru, Hayashi, Toshinobu, Ayuhara, Hideaki, Harada, Tomohiko, Tamaki, Shinya, Maeda, Akimitsu, Ohashi, Yasukata, Arakawa, Yuichiro, Fujita, Yukiyoshi, Yamamoto, Keisuke, Miyamoto, Yasunori, Yano, Takuya, and Itoh, Kunihiko

Published
2023
Full Text
View/download PDF

5. Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study).

Author

Hatori, Masahiro, Tsuji, Daiki, Suzuki, Kenichi, Yokokawa, Takashi, Kawakami, Kazuyoshi, Moriyama, Ryo, Osada‐Tsuchiya, Marika, Otake, Aki, Nakao, Masahiko, Yano, Takuya, Arakawa, Yuichiro, Matsuo, Keisuke, Ohashi, Yasukata, Sakata, Yasuhiko, Kogure, Yuki, Tamaki, Shinya, Wada, Atsushi, Taki, Yusuke, Sasahira, Naoki, and Ishii, Hiroshi

Subjects
*SOMATIC mutation, *GENETIC polymorphisms, *RIBONUCLEOSIDE diphosphate reductase, *LOGISTIC regression analysis
Abstract

Background: Genetic polymorphisms of molecules are known to cause individual differences in the therapeutic efficacy of anticancer drugs. However, to date, germline mutations (but not somatic mutations) for anticancer drugs have not been adequately studied. The objective of this study was to investigate the association between germline polymorphisms of gemcitabine metabolic and transporter genes with carbohydrate antigen 19‐9 (CA 19‐9) response (decrease ≥50% from the pretreatment level at 8 weeks) and overall survival (OS) in patients with metastatic pancreatic cancer who receive gemcitabine‐based chemotherapy. Methods: This multicenter, prospective, observational study enrolled patients with metastatic pancreatic cancer patients who were receiving gemcitabine monotherapy or gemcitabine plus nanoparticle albumin‐bound paclitaxel combination chemotherapy. Thirteen polymorphisms that may be involved in gemcitabine responsiveness were genotyped, and univariate and multivariate logistic regression analyses were used to determine the association of these genotypes with CA 19‐9 response and OS. The significance level was set at 5%. Results: In total, 180 patients from 11 hospitals in Japan were registered, and 159 patients whose CA 19‐9 response could be assessed were included in the final analysis. Patients who had a CA 19‐9 response had significantly longer OS (372 vs. 241 days; p =.007). RRM1 2464A>G and RRM2 175T>G polymorphisms suggested a weak association with CA 19‐9 response and OS, but it was not statistically significant. COX‐2 −765G>C polymorphism did not significantly correlate with CA 19‐9 response but was significantly associated with OS (hazard ratio, 2.031; p =.019). Conclusions: Genetic polymorphisms from the pharmacokinetics of gemcitabine did not indicate a significant association with efficacy, but COX‐2 polymorphisms involved in tumor cell proliferation might affect OS. This study investigated the association between germline polymorphisms of gemcitabine metabolic and transporter genes and carbohydrate 19‐9 response and overall survival in patients with metastatic pancreatic cancer who were receiving gemcitabine‐based chemotherapy. Germline polymorphisms of the metabolic pathway and transporter genes in gemcitabine were not significantly associated with efficacy, but COX‐2 polymorphisms were associated with overall survival. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Pharmacogenomic study of gemcitabine on the safety and efficacy in patients with metastatic pancreatic cancer (GENESECT study): Analysis of a subpopulation.

Author

Yokokawa, Takashi, primary, Tsuji, Daiki, additional, Hatori, Masahiro, additional, Suzuki, Kenichi, additional, Kawakami, Kazuyoshi, additional, Nakao, Masahiko, additional, Yano, Takuya, additional, Arakawa, Yuichiro, additional, Matsuo, Keisuke, additional, Ohashi, Yasukata, additional, Ozaka, Masato, additional, Sasahira, Naoki, additional, Sakata, Yasuhiko, additional, Kogure, Yuki, additional, Tamaki, Shinya, additional, Wada, Atsushi, additional, Taki, Yusuke, additional, Ishii, Hiroshi, additional, Itoh, Kunihiko, additional, and Yamaguchi, Masakazu, additional

Published
2024
Full Text
View/download PDF

9. A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-

Author

Tsuji, Daiki, primary, Nakagaki, Shigeru, additional, Yonezawa, Itsuki, additional, Suzuki, Kenichi, additional, Yokokawa, Takashi, additional, Kawasaki, Yohei, additional, Yamaguchi, Takumi, additional, Kawaguchi, Takashi, additional, Hatori, Masahiro, additional, Matsumoto, Takuma, additional, Sakata, Yukio, additional, Yamamoto, Keisuke, additional, Nishimura, Tomoyasu, additional, Kogure, Yuki, additional, Hayashi, Toshinobu, additional, Osawa, Misa, additional, Itoh, Kunihiko, additional, and Watanabe, Masaya, additional

Published
2023
Full Text
View/download PDF

10. Influence of menopause on chemotherapy‐induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study

Author

Yokokawa, Takashi, primary, Suzuki, Kenichi, additional, Tsuji, Daiki, additional, Hosonaga, Mari, additional, Kobayashi, Kazuo, additional, Kawakami, Kazuyoshi, additional, Kawazoe, Hitoshi, additional, Nakamura, Tomonori, additional, Suzuki, Wataru, additional, Sugisaki, Takahito, additional, Aoyama, Takeshi, additional, Hashimoto, Koki, additional, Hatori, Masahiro, additional, Tomomatsu, Takuya, additional, Inoue, Ayaka, additional, Azuma, Keiichi, additional, Asano, Maimi, additional, Takano, Toshimi, additional, Ohno, Shinji, additional, and Yamaguchi, Masakazu, additional

Published
2023
Full Text
View/download PDF

15. Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)

Author

Shimizu, Hisanori, Suzuki, Kenichi, Uchikura, Takeshi, Tsuji, Daiki, Yamanaka, Takeharu, Hashimoto, Hironobu, Goto, Koichi, Matsui, Reiko, Seki, Nobuhiko, Shimada, Toshikazu, Ikeda, Shunya, Ikegami, Naoki, Hama, Toshihiro, Yamamoto, Nobuyuki, and Sasaki, Tadanori

Published
2018
Full Text
View/download PDF

23. Chemotherapy-induced neutropenia as a prognostic factor in patients with extensive-stage small cell lung cancer

Author

Miyagi, Takehiro, primary, Tsuji, Daiki, additional, Kawasakai, Yohei, additional, Ishikawa, Hiroshi, additional, Tanaka, Rei, additional, Nakao, Masahiko, additional, Nakagaki, Shigeru, additional, Hayashi, Toshinobu, additional, Ayuhara, Hideaki, additional, Harada, Tomohiko, additional, Tamaki, Shinya, additional, Maeda, Akimitsu, additional, Ohashi, Yasukata, additional, Arakawa, Yuichiro, additional, Fujita, Yukiyoshi, additional, Yamamoto, Keisuke, additional, Miyamoto, Yasunori, additional, Yano, Takuya, additional, and Itoh, Kunihiko, additional

Published
2022
Full Text
View/download PDF

28. Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting:A systematic review and meta-analysis

Author

Eliasen, Astrid, Dalhoff, Kim, Mathiasen, René, Schmiegelow, Kjeld, Rechnitzer, Catherine, Schelde, Astrid Blicher, Perwitasari, Dyah Aryani, Tsuji, Daiki, Brok, Jesper, Eliasen, Astrid, Dalhoff, Kim, Mathiasen, René, Schmiegelow, Kjeld, Rechnitzer, Catherine, Schelde, Astrid Blicher, Perwitasari, Dyah Aryani, Tsuji, Daiki, and Brok, Jesper

Abstract

A substantial proportion of cancer patients experience chemotherapy-induced nausea and vomiting (CINV) despite the use of antiemetic drugs. Prevalent genetic polymorphisms involved in antiemetic drug metabolism, drug transport and receptor pathways likely affect the effectiveness of antiemetics. Knowledge on which polymorphisms to integrate into individualised clinical care is needed. We did a systematic review evaluating the association between polymorphisms and effectiveness of antiemetics in cancer patients receiving moderately to highly emetogenic chemotherapy. Twenty studies n = 2331 evaluated eight polymorphisms in five candidate genes involved in 5-HT3 antagonist pathways. HTR3C C1214G increased the risk of acute chemotherapy-induced vomiting in the dominant model (odds ratio (OR) = 2.67, 95 % confidence interval (CI): 1.08–6.63). ABCB1 C3435T reduced the risk of acute CINV in the recessive model (OR = 0.60, 95 % CI: 0.44-0.81). Future studies should evaluate candidate genes that affect pharmacogenetics of other antiemetics beside 5-HT3 antagonists.

Published
2020

32. Analysis of pharmacogenomic factors for chemotherapy-induced nausea and vomiting in patients with breast cancer receiving doxorubicin and cyclophosphamide chemotherapy

Author

Tsuji, Daiki, primary, Matsumoto, Megumi, additional, Kawasaki, Yohei, additional, Kim, Yong-I. L., additional, Yamamoto, Keisuke, additional, Nakamichi, Hidenori, additional, Sahara, Yuri, additional, Makuta, Ryo, additional, Yokoi, Mari, additional, Miyagi, Takehiro, additional, and Itoh, Kunihiko, additional

Published
2020
Full Text
View/download PDF

33. ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy

Author

Nomura, Hisanaga, primary, Tsuji, Daiki, additional, Demachi, Ken, additional, Mochizuki, Nobuo, additional, Matsuzawa, Haruki, additional, Yano, Tomonori, additional, Daiko, Hiroyuki, additional, Fujii, Satoshi, additional, Kojima, Takashi, additional, Itoh, Kunihiko, additional, and Kawasaki, Toshikatsu, additional

Published
2020
Full Text
View/download PDF

36. Additional file 1: of Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial)

Author

Shimizu, Hisanori, Suzuki, Kenichi, Uchikura, Takeshi, Tsuji, Daiki, Takeharu Yamanaka, Hashimoto, Hironobu, Goto, Koichi, Matsui, Reiko, Seki, Nobuhiko, Shimada, Toshikazu, Shunya Ikeda, Ikegami, Naoki, Hama, Toshihiro, Yamamoto, Nobuyuki, and Sasaki, Tadanori

Abstract

Figure S1. The structure of the category and effect measurement of CINV. The CR rates in the TRIPLE study were 59.1% (244/413 patients) for the GRA group and 65.7% (272/414 patients) for the PALO group. Regarding the case of CR or non-CR, we devised three categories according to the development of overall CINV as well as acute and delayed CINV (category 1, CR [0â 120â h]; category 2, non-CR delayed; category 3, non-CR acute). (PPTX 83 kb)

Published
2018
Full Text
View/download PDF

37. Anti-Idiotype DNA Aptamer Affinity Purification–High-Temperature Reversed-Phase Liquid Chromatography: A Simple, Accurate, and Selective Bioanalysis of Bevacizumab

Author

Yamada, Tomohiro, primary, Saito, Taro, additional, Shimizu, Yutaka, additional, Tsukakoshi, Kaori, additional, Hayashi, Hideki, additional, Mizuno, Hajime, additional, Tsuji, Daiki, additional, Yamamoto, Keisuke, additional, Itoh, Kunihiko, additional, Toyo’oka, Toshimasa, additional, Ikebukuro, Kazunori, additional, and Todoroki, Kenichiro, additional

Published
2019
Full Text
View/download PDF

38. Effects of Chemotherapy-Induced Neutropenia on Overall Survival in Patients With Unresectable or Metastatic Urothelial Carcinoma to Gemcitabine Plus Cisplatin Combination Chemotherapy

Author

Yamamoto, Keisuke, primary, Sasano, Tomomi, additional, Tsuji, Daiki, additional, Ishizuka, Yuichi, additional, Tokou, Umi, additional, Nakamichi, Hidenori, additional, Yoneda, Tatsuaki, additional, Shiokawa, Mitsuru, additional, and Yabe, Katsushige, additional

Published
2019
Full Text
View/download PDF

39. Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial

Author

Tsuji, Daiki, primary, Suzuki, Kenichi, additional, Kawasaki, Yohei, additional, Goto, Koichi, additional, Matsui, Reiko, additional, Seki, Nobuhiko, additional, Hashimoto, Hironobu, additional, Hama, Toshihiro, additional, Yamanaka, Takeharu, additional, Yamamoto, Nobuyuki, additional, and Itoh, Kunihiko, additional

Published
2018
Full Text
View/download PDF

40. Drug-related genetic polymorphisms affecting severe chemotherapy-induced neutropenia in breast cancer patients

Author

Tsuji, Daiki, Ikeda, Midori, Yamamoto, Keisuke, Nakamori, Harumi, Kim, Yong-Il, Kawasaki, Yohei, Otake, Aki, Yokoi, Mari, Inoue, Kazuyuki, Hirai, Keita, Nakamichi, Hidenori, Tokou, Umi, Shiokawa, Mitsuru, and Itoh, Kunihiko

Subjects
Neutropenia, Polymorphism, Genetic, Observational Study, Breast Neoplasms, Middle Aged, doxorubicin, Severity of Illness Index, Hospitalization, breast cancer, Antineoplastic Combined Chemotherapy Protocols, ComputingMethodologies_DOCUMENTANDTEXTPROCESSING, genetic polymorphism, Humans, cyclophosphamide, Female, Research Article
Abstract

Supplemental Digital Content is available in the text, Chemotherapy-induced neutropenia (CIN) is one of the major adverse events that necessitate chemotherapy dose reduction. This study aimed to evaluate the association between grade 4 neutropenia and genetic polymorphisms in breast cancer patients. In this genetic polymorphism association study, peripheral blood samples from 100 consecutive breast cancer outpatients, between August 2012 and September 2014, treated with doxorubicin and cyclophosphamide (AC) combination chemotherapy were genotyped for polymorphisms in adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1), cytochrome P450 (CYP) enzyme-coding genes (CYP2B6 and CYP3A5), glutathione S-transferase (GST), and excision repair cross-complementing 1 (ERCC1). Associations between grade 4 neutropenia and genotypes as well as risk factors were examined using multivariate logistic regression. From 100 patients, 32.0% had grade 4 neutropenia. Multivariate logistic regression analysis revealed that ERCC1 118C > T (odds ratio [OR], 3.43; 95% confidence interval [CI], 1.22–9.69; P = 0.020), CYP2B6∗6 (OR, 4.51; 95% CI, 1.21–16.95; P = 0.025), body mass index (BMI) (OR, 6.94; 95% CI, 1.15–41.67; P = 0.035), and baseline white blood cell (WBC) count (OR, 2.99; 95% CI, 1.06–8.40; P = 0.038) were significant predictors of grade 4 neutropenia. ERCC1 and CYP2B6 gene polymorphisms were associated with the extent of grade 4 neutropenia in patients receiving AC chemotherapy. In addition to previously known risk factors, BMI and WBC counts, ERCC1 and CYP2B6 gene polymorphisms were also identified as independent strong predictors of grade 4 neutropenia.

Published
2016

41. Genetic risk factors for chemotherapy-induced nausea and vomiting in patients with cancer receiving cisplatin-based chemotherapy

Author

Yokoi, Mari, primary, Tsuji, Daiki, additional, Suzuki, Kenichi, additional, Kawasaki, Yohei, additional, Nakao, Masahiko, additional, Ayuhara, Hideaki, additional, Kogure, Yuuki, additional, Shibata, Kazuhiko, additional, Hayashi, Toshinobu, additional, Hirai, Keita, additional, Inoue, Kazuyuki, additional, Hama, Toshihiro, additional, Takeda, Koji, additional, Nishio, Makoto, additional, and Itoh, Kunihiko, additional

Published
2017
Full Text
View/download PDF

44. Comprehensive study of risk factors for chemotherapy-induced nausea and vomiting in cancer patients receiving cisplatin-based chemotherapy: A TRIPLE pharmacogenomics study.

Author

Ayuhara, Hideaki, primary, Tsuji, Daiki, additional, Yokoi, Mari, additional, Suzuki, Kenichi, additional, Kawasaki, Yohei, additional, Nakao, Masahiko, additional, Kogure, Yuki, additional, Shibata, Kazuhiko, additional, Hayashi, Toshinobu, additional, Hirai, Keita, additional, Inoue, Kazuyuki, additional, Hama, Toshihiro, additional, Takeda, Koji, additional, Nishio, Makoto, additional, and Itoh, Kunihiko, additional

Published
2017
Full Text
View/download PDF

45. Comparative Investigation of the Antiemetic Efficacy of Aprepitant Containing Antiemetic Regimen in Breast Cancer Patients Receiving Doxorubicin and Cyclophosphamide Combination Chemotherapy

Author

Makuta, Ryo, primary, Tsuji, Daiki, additional, Kim, Yong-Il, additional, Yamamoto, Keisuke, additional, Otake, Aki, additional, Yokoi, Mari, additional, Nakamori, Harumi, additional, Inoue, Kazuyuki, additional, Hirai, Keita, additional, Nakamichi, Hidenori, additional, Shiokawa, Mitsuru, additional, and Itoh, Kunihiko, additional

Published
2017
Full Text
View/download PDF

47. Effects of Chemotherapy-Induced Neutropenia on Overall Survival in Patients With Unresectable or Metastatic Urothelial Carcinoma to Gemcitabine Plus Cisplatin Combination Chemotherapy.

Author

Keisuke Yamamoto, Tomomi Sasano, Daiki Tsuji, Yuichi Ishizuka, Umi Tokou, Hidenori Nakamichi, Tatsuaki Yoneda, Mitsuru Shiokawa, Katsushige Yabe, Yamamoto, Keisuke, Sasano, Tomomi, Tsuji, Daiki, Ishizuka, Yuichi, Tokou, Umi, Nakamichi, Hidenori, Yoneda, Tatsuaki, Shiokawa, Mitsuru, and Yabe, Katsushige

Published
2019
Full Text
View/download PDF

49. Influence of Genetic Polymorphisms and Concomitant Anxiolytic Doses on Antidepressant Maintenance Doses in Japanese Patients with Depression

Author

Inoue, Kazuyuki, primary, Murofushi, Takuma, additional, Nagaoka, Kakeru, additional, Ando, Natsuko, additional, Hakamata, Yasuhiro, additional, Suzuki, Akiko, additional, Umemura, Akiko, additional, Yoshida, Yuko, additional, Hirai, Keita, additional, Tsuji, Daiki, additional, and Itoh, Kunihiko, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results